THE INVESTOR] Alteogen is accelerating the development of a biosimilar version of the world’s top breast cancer drug Herceptin to join two other Korean firms in challenging big pharma Roche.
Alteogen, a Korean developer of biosimilars, said Wednesday it would transfer the technology of its ALT-L2, a biosimilar product of breast and gastric cancer treatment Herceptin, to China’s Qilu Pharm
Date Alteogen patents (updated weekly) - BOOKMARK this page
DISCLOSURE] Alteogen (196170) said on Dec. 22 that its biosimilar of Roche’s breast cancer antibody Herceptin has cleared phase 1 clinical trials in Canada.
 1  2  3